Lynavoy (linerixibat)
Intercept Pharmaceuticals
ApprovedMar 17, 2026
Marketer take
Targets cholestatic itch in primary biliary cholangitis, a symptom-focused niche next to disease-modifying drugs like Iqirvo and Livdelzi, so hepatologists and gastroenterologists will hear quality-of-life messaging.
- Sponsor company
- Intercept Pharmaceuticals
- Indication
- To treat cholestatic pruritus associated with primary biliary cholangitis
- Therapeutic area
- Hepatology
- Event
- FDA approval
- Date
- Mar 17, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?